Switching From Morphine to Methadone. A Clinical, Pharmacological and Pharmacogenetic Study
Information source: Norwegian University of Science and Technology
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cancer
Intervention: Methadone (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Norwegian University of Science and Technology Official(s) and/or principal investigator(s):
Stein Kaasa, MD,PhD Prof., Principal Investigator, Affiliation: St Olavs University Hospital, Trondheim
Summary
Cancer patients on morphine for chronic pain, with side effects or unsatisfactory pain
relief, will be rotated to Methadone. We will try to find out what is the best methode to
rotate, and the equivalent dosage.
Clinical Details
Official title: Switching From Morphine to Methadone. A Clinical, Pharmacological and Pharmacogenetic Study
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: The overall aim of the present study is to validate the switching procedure from morphine to methadone for patients with advanced cancer and a short life expectancy. More specifically, we will:
Secondary outcome: Collect blood samples for present and future genetic analyses in order to explore inter individual variations in methadone and morphine doses based upon possible polymorphisms.Compare the QT-intervals on electrocardiograms obtained before and after start with methadone.
Detailed description:
This study is based on the clinical observation that patients who are not well controlled on
morphine or oxycodone may benefit from switching to another opioid, in this case methadone.
Although the mechanism for such switch is not completely understood, evidence indicates that
opioids with different chemical structures have different characteristics, not least in
relation to new knowledge about genetic variation in opioid receptors. Another challenge is
that there is much uncertainty regarding equianalgesic dose ratios for morphine and
methadone. It seems that the higher the morphine doses, the relatively lower methadone doses
are needed to substitute morphine. Furthermore, there is uncertainty to which switching
procedures one should use, the most common ones are "stop and go" and a three days switch.
Finally, it is reported that methadone may increase the QT interval of the ECG, and thus
increase the risk for the ventricular arrhythmia Torsade de pointe. The aim of this
randomized, open label, multicenter study is primarily to compare the switching procedures,
but it will also provide more knowledge about equianalgesic dose ratios, the effect of
methadone on the QT interval, genetical factors that may characterize patients needing
opioid switch as well as their response to it, and finally if pharmacokinetic factors
plays a role.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- • Malignant disease.
- On morphine and in need of opioid rotation. (A patient in need of opioid
rotation is defined as having insufficient pain control with or without
unacceptable side effects from opioids).
- Able to complete the planned assessment schedules.
- Above 18 years of age.
- If out-patient, the patient lives with someone who can observe him/her.
- Given informed consent according to the ethical guidelines.
Exclusion Criteria:
- Not able to read or write in Norwegian
- The patient has participated in a clinical study 4 weeks prior to inclusion
Locations and Contacts
St Olavs Hospital, Trondheim 7006, Norway
Additional Information
Starting date: August 2004
Last updated: February 27, 2014
|
